WuXi Biologics, a wholly owned subsidiary of WuXi PharmaTech (Cayman) Inc., a contract service provider serving the global pharmaceutical, biotechnology, and medical device industries, has begun construction on a new $150 million biologics manufacturing facility in Wuxi city in China.

The new mammalian cell-culture manufacturing facility will use disposable bioreactors. The new facility is to be completed by January 2017 and will house fourteen 2000-L disposable bioreactors for fed-batch cell culture and two 1000-L bioreactors for perfusion runs. The facility will also be built to run advanced continuous or semi-continuous manufacturing processes in addition to traditional fed-batch and perfusion modes.

This facility further expands WuXi’s biologics manufacturing capabilities. In August 2012, WuXi completed a biologics clinical drug substance and drug product manufacturing facilities in Wuxi city, a facility that met cGMP standards of the United States, the European Union (EU), and China. Since then, the facilities have ramped up to produce clinical supplies for the US, EU, China,and other markets.

Source: WuXi PharmaTech